GlobalData on MSN2d
Abcuro secures $200m as it eyes approval for rare muscle disease drug
The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.
BioSpace2d
Abcuro Secures $200 Million Series C to Push Rare Muscle Disease Treatment
The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...
pharmaphorum2d
Abcuro raises $200m to take muscle disease drug to market
US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...
Newton biotech gets $200M for rare muscle disease drug
Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...
Medscape16d
Sporadic Inclusion Body Myositis-Diagnosis, Pathogenesis and Therapeutic Strategies
Sporadic inclusion body myositis (sIBM) presents with a characteristic ... pathways might prove helpful in arresting disease progression. sIBM is often misdiagnosed as polymyositis or other ...
Medscape18d
Sporadic Inclusion Body Myositis-Diagnosis, Pathogenesis and Therapeutic Strategies
sIBM is a complex disorder, the underlying cause of which is unclear. The observation that the intact muscle fibers are invaded by T lymphocytes, whereas the vacuolated fibers lack T-cell ...
Business Insider1y
Diversity and Inclusion
Yet here's why some advocates are still wary. Companies are going to continue addressing diversity and inclusion because they're being held accountable in new ways, including from politicians.